Drug profile · INN
sofosbuvir
EPCLUSA
sofosbuvir (EPCLUSA) is a rna-directed rna polymerase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — sofosbuvir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 2
- Programs
- 10
- Data quality
- 0.89
Quick answer
sofosbuvir (EPCLUSA) is a rna-directed rna polymerase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
RNA-directed RNA polymerase inhibitor
Primary target: RNA-directed RNA polymerase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is sofosbuvir?
sofosbuvir (EPCLUSA) is a rna-directed rna polymerase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sofosbuvir?
EPCLUSA is a marketed brand name for sofosbuvir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sofosbuvir?
sofosbuvir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.